Epicyte Pharmaceuticals

Most common—corn Environment friendly Dow, Monsanto, Sigma-Aldrich, Prodigen, Epicyte Pharmaceutical developing products No virus transmission though contained Fear of getting into food chain... 

Crabtree, P., Epicyte Pharmaceutical joins failing-biotech row. http //www.checkbiotech.org/ root/index.cfm fuseaction=search sea rch= %20epicyte doc id =7731 start= l fullsearch=l, 2004. 

Epicyte Pharmaceutical Dow, Centocor Anti-HSV antibody Corn Phase 1... 

One major advantage of monoclonal antibodies from plants is the potential low cost of large-scale production. There are commercial companies (such as EPIcyte Pharmaceutical Inc) who are planning clinical dials for plant-produced secretory antibodies for human therapy. These so-called plantibodies can be produced at an estimated cost of 0.01 to 0.1/mg as opposed to 1 to 5/mg for production from cell culture processing of animal-derived hybridomas. The cost of microbial fermentation is lower than that of mammalian cell culture but bacteria lack the ability for efficient multimeric protein assembly and of any post-translational modification. A further potential advantage of the plantibodies is delivery by consumption of plant tissue and thus avoiding any need of purification. These possibilities are particularly applicable in certain cases such as the previously shown ability of a plant-produced... 

---